Nanoplatform Based Intranasal Vaccines: Current Progress and Clinical Challenges
Open Access
- 26 August 2024
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (36) , 24650-24681
Abstract
Multiple vaccine platforms have been employed to develop the nasal SARS-CoV-2 vaccines in preclinical studies, and the dominating pipelines are viral vectored as protein-based vaccines. Among them, several viral vectored-based vaccines have entered clinical development. Nevertheless, some unsatisfactory results were reported in these clinical studies. In the face of such urgent situations, it is imperative to rapidly develop the next-generation intranasal COVID-19 vaccine utilizing other technologies. Nanobased intranasal vaccines have emerged as an approach against respiratory infectious diseases. Harnessing the power of nanotechnology, these vaccines offer a noninvasive yet potent defense against pathogens, including the threat of COVID-19. The improvements made in vaccine mucosal delivery technologies based on nanoparticles, such as lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles etc., not only provide stability and controlled release but also enhance mucosal adhesion, effectively overcoming the limitations of conventional vaccines. Hence, in this review, we overview the evaluation of intranasal vaccine and highlight the current barriers. Next, the modern delivery systems based on nanoplatforms are summarized. The challenges in clinical application of nanoplatform based intranasal vaccine are finally discussed.Keywords
Funding Information
- National Natural Science Foundation of China (U19A2003)
- Excellent Young Scientists Fund (32122052)
This publication has 400 references indexed in Scilit:
- A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta variantsJournal of Extracellular Vesicles, 2022
- Biomaterials‐Based Delivery of Therapeutic Antibodies for Cancer TherapyAdvanced Healthcare Materials, 2021
- Modularly Programmable Nanoparticle Vaccine Based on Polyethyleneimine for Personalized Cancer ImmunotherapyAdvanced Science, 2021
- Biomedical applications of carbon nanomaterials: Drug and gene delivery potentialsJournal of Cellular Physiology, 2018
- Non‐clinical safety evaluation of repeated intramuscular administration of the AS15 immunostimulant combined with various antigens in rabbits and cynomolgus monkeysJournal of Applied Toxicology, 2015
- A Serum‐Tolerant Hydroxyl‐Modified Polyethylenimine as Versatile Carriers of pDNA/siRNAMacromolecular Bioscience, 2013
- Applications of Nanoparticles in BiologyAdvanced Materials, 2008
- Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug deliveryJournal of Pharmaceutical Sciences, 2006
- Soft Nanotechnology with Soft NanoparticlesAngewandte Chemie International Edition, 2005
- ISCOMs: an adjuvant with multiple functionsJournal of Leukocyte Biology, 1998